At least 42,000 Americans and 70,000 Europeans will be diagnosed with pancreatic cancer in 2020.1 The number could be as high as 57,000 in the US, where the disease is the 9th most commonly diagnosed cancer in women, and the 10th most common in men.2 Moreover, it is the 3rd deadliest form of cancer with a survival rate over 5 years from diagnosis of only 5-8%.1

If we could detect the disease earlier – when the cancer is still resectable – we could improve survival rates. We could increase the clinicians’ treatment options. And increase patient quality of life and life expectancy.

To this date (July 2020), there is no reliable, blood based diagnostic test for pancreatic cancer that is sensitive and accurate enough to improve patient management by detecting the cancer in early stages.

To raise awareness for pancreatic cancer it is crucial to support research, patients and their families. One way of doing that is to join Immunovia WALK 2020.

Learn more about Immunovia’s Q4 2020 launch of IMMray™ PanCan-d, a blood test developed for early detection of pancreatic cancer.

References:

  1. Immunovia.com
  2. SEER Fact Sheets: Pancreatic Cancer 2016.
  3. Pancan.org